Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04276597
Previous Study | Return to List | Next Study

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. (PUTNET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04276597
Recruitment Status : Recruiting
First Posted : February 19, 2020
Last Update Posted : October 9, 2020
Sponsor:
Information provided by (Responsible Party):
Excel Diagnostics and Nuclear Oncology Center

Brief Summary:

Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other non-.GEP-NET.

The treatment regimen will consist of 4 doses of 200 (±10%) mCi 177Lu-DOTATOC administered at 8+/- 1-week intervals.


Condition or disease Intervention/treatment Phase
Pulmonary Neuroendocrine Neoplasm Pheochromocytoma Paraganglioma Thymus Carcinoid Unknown Primary Tumors Neuroendocrine Tumors Neuroendocrine Skin Carcinoma Neuroendocrine Breast Tumor Neuroendocrine Carcinoma Metastatic Neuroendocrine Neoplasm of Ovary Drug: 177Lu-DOTATOC Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored Study to Determine the Safety and Effectiveness of Lu-177 DOTATOC in Adult Subjects With Somatostatin Receptor Expressing Pulmonary, Pheochromocytoma, paragangliomUnknown Primary, and Thymus Neuroendocrine Tumors (PUTNET) or Any Other Non-.GEP-NET.
Estimated Study Start Date : November 2020
Estimated Primary Completion Date : March 30, 2021
Estimated Study Completion Date : March 30, 2022


Arm Intervention/treatment
Experimental: Lu177 DOTATOC treatment
4 doses of 200mCi 177Lu- DOTATOC PRRT
Drug: 177Lu-DOTATOC
177Lu labeled somatostatin receptors targeting ligand




Primary Outcome Measures :
  1. Assessment of the overall response rate [ Time Frame: 12 monts ]
    determined using standard of care scans NETSPOT PET/CT, Octreoscan SPECT/CT, MRI


Secondary Outcome Measures :
  1. Progression Free Survival (rPFS) in subjects receiving 4 cycles of therapy Monitoring of the changes in quality of life (QOL) through assessment of ECOG performance status and a QOL subject questionnaire. [ Time Frame: 12 months ]
    determined using standard of care scans NETSPOT PET/CT, Octreoscan SPECT/CT, MRI



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Signed informed consent.
  • Subjects of either sex, aged ≥18 years.
  • ECOG status 0-2.
  • Life-expectancy of at least 12 weeks.
  • Histologically/cytologically confirmed diagnosis of SSTR (+) neuroendocrine tumors of the lung, Pheochromocytoma, Paraganglioma, thymus, and unknown primary, unresectable or metastatic.
  • Measurable disease per RECIST 1.1, on CT/MRI scans, defined as at least 1 lesion with ≥ 1 cm in longest diameter (lymph nodes along short axis >15 mm).
  • Appropriate diagnostic imaging studies, at the discretion of the P.I. including but not limited to CT, MRI , 18F-FDG PET/CT, NAF PET/CT bone scan, ultrasound, etc. of the tumor region or suspected area within the 4 weeks of dosing day.
  • Somatostatin receptor positive (SSTR+) disease, as evidenced by available FDA, commercially of IND approved SSTR imaging (SRI), within 4 weeks prior to the first cycle
  • Recent blood test results (within 2weeks pre-dose) as follows:
  • Sufficient bone marrow capacity as defined by WBC ≥2,500/µl and WBC≥2,000/mm3 for subsequent cycles; platelets ≥ 100,000 (100 * 103/mm3) for the first treatment and ≥75,000 for the subsequent therapies, Hgb ≥8.9 g/dl for the first treatment and 8.0 g/dl for the subsequent therapies, ANC ≥1500/mm3 for the first treatment and ≥1000/ mm3; for the subsequent therapies.
  • ALT, AST values ≤3 times ULN
  • Bilirubin: ≤3 times ULN
  • Serum creatinine ≤ 150 µmol/liter or 1.7 mg/dl
  • Negative pregnancy test in women capable of child-bearing within 48 hours of IMP administration.
  • Serum albumin > 3.0g/L (<3 g/L may be acceptable at the discretion of investigator, if PT, PTT, and INR are within normal range)
  • All available FDA-approved therapies for which the subject is eligible have been exhausted (with the exception of PRRT), unless available therapies are refused by the subject (with the exception of somatostatin analogue, octreotide, and somatuline).

Exclusion Criteria:

  • Known hypersensitivity to any of the excipients of Lu-177 DOTATOC.
  • Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (within 28 days) and Sandostatin® (within 1 day) prior to treatment.
  • Subjects with unusual hematological parameters, including an increased MCV (>105fL), and especially in those who had previous chemotherapy, the advice of a hematologist should be sought for adequate further work-up
  • Any subject who is taking concomitant medications that decrease renal function (such as aminoglycoside antibiotics).
  • Female subjects who are pregnant, lactating or women of childbearing potential not willing to practice effective contraceptive techniques during the study period and for 67 days (more than 10 half-lives of 177Lu after the last treatment, or male subjects who have female partners of childbearing potential not willing to practice abstinence or effective contraception, during the study period and for 67 days after the last treatment.
  • Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study.
  • Indication for surgical lesion removal with curative potential
  • Planned (for the period of study participation): chemotherapy, immunotherapy, radiation therapy (unless regional for pain relief) chemo-embolization, bland embolization, radio-embolization, treatment with cyclosporine-A.
  • Known brain metastases; unless these metastases have been treated and stabilized 6 months prior to enrolment
  • Completion of: (1) cytotoxic chemotherapy for less than 6 weeks; (2) a biological agent for less than 5 half-lives; and (3) radiation therapy (except regional for pain relief) for less than 6 weeks prior to study enrolment,
  • Uncontrolled congestive heart failure; subjects suspected of having this condition need to show ejection fraction of > 35% as determined by MUGA scan.
  • Glomerular Filtration Rate (GFR) < 35 mL/min
  • Subjects with prior peptide receptor radionuclide therapy (PPRT).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04276597


Contacts
Layout table for location contacts
Contact: Susan Cork 713-781-6200 scork@exceldiagnostics.com
Contact: Rouzebeh Esfandiari, MD resfandiari@exceldiagnostics.com

Locations
Layout table for location information
United States, Texas
Excel Diagnostics and Nuclear Oncology Center Recruiting
Houston, Texas, United States, 77042
Contact: Susan Cork    713-341-3203    scork@exceldiagnostics.com   
Contact: Izabela Tworowska, PhD    713-590-0601    itworowska@radiomedix.com   
Sub-Investigator: Ayman Gaber, MD         
Sub-Investigator: Afshin Shafie, MD         
Sub-Investigator: Rodolfo Nunez, MD         
Principal Investigator: Ebrahim Delpassand, MD         
Sponsors and Collaborators
Excel Diagnostics and Nuclear Oncology Center
Investigators
Layout table for investigator information
Principal Investigator: Ebrahim Delpassand, MD Excel Diagnostics and Nuclear Oncology Center
Study Director: Rodolfo Nunez, MD Excel Diagnostics and Nuclear Oncology Center
Study Director: Afshin Shafie, MD Excel Diagnostics and Nuclear Oncology Center
Study Director: Ayman Gaber, MD Excel Diagnostics and Nuclear Oncology Center
Layout table for additonal information
Responsible Party: Excel Diagnostics and Nuclear Oncology Center
ClinicalTrials.gov Identifier: NCT04276597    
Other Study ID Numbers: 143631
First Posted: February 19, 2020    Key Record Dates
Last Update Posted: October 9, 2020
Last Verified: September 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Excel Diagnostics and Nuclear Oncology Center:
Neuroendocrine tumors
Thymus neuroendocrine
Unknown Primary
Paraganglioma
Pheochromocytoma
Pulmonary
Any other non-.GEP-NET
NET
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Merkel Cell
Carcinoma
Neoplasms
Neuroendocrine Tumors
Carcinoma, Neuroendocrine
Pheochromocytoma
Breast Neoplasms
Paraganglioma
Carotid Body Tumor
Neoplasms, Unknown Primary
Ovarian Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Adenocarcinoma
Neoplasms by Site
Breast Diseases
Skin Diseases
Paraganglioma, Extra-Adrenal
Neoplasm Metastasis
Neoplastic Processes
Pathologic Processes
Endocrine Gland Neoplasms
Ovarian Diseases
Adnexal Diseases
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases